Celltrion Wins Race For High-Concentration Adalimumab
Receives Positive CHMP Opinion For 100mg/ml Biosimilar To Humira
Celltrion expects to receive the world’s first approval for a high-concentration adalimumab biosimilar rival to Humira, after receiving a positive opinion from the EMA’s CHMP for its CT-P17 candidate.
